Skip to content

Confirmation of the effects of food intake on cognitive function in healthy subjects

Confirmation of the effects of food intake on cognitive function in healthy subjects - Confirmation of the effects of food intake on cognitive function in healthy subjects

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
JPRN
Registry ID
JPRN-UMIN000056072
Enrollment
20
Registered
2024-11-17
Start date
2024-11-18
Completion date
Unknown
Last updated
2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Healthy adult

Interventions

One packet (30.0 g as solids) of the test food is dissolved in the prescribed amount of water (120 mL) and taken at once One packet (30.0 g of solids) of placebo is dissolved in the prescribed amount

Sponsors

EP Mediate Co., Ltd.
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: (1) Healthy males and females from 20 to 64 years of age (2) Those whose first language is Japanese (3) BMI at the time of pre-examination is 18.5 kg/m 2 or more and less than 30 kg/m 2 (4) Those who do not have abnormalities in fasting blood glucose at the time of pre-examination and changes in blood glucose after maltodextrin loading (5) Those who fully understand the purpose and content of the research and agree to participate in the research of their own free will

Exclusion criteria

Exclusion criteria: (1) Those who have a habit of drinking alcohol on a daily basis (40 g or more of alcohol equivalent/day), and those who have lifestyle habits that interfere with evaluation, such as irregular sleep schedule. (2) Those who are judged to be unsuitable as subjects based on the results of the pre-examination (3) Those who are prescribed or regularly use medications that may affect cognitive function (4) Those who consume health foods such as specified health foods and functional foods related to cognitive function at least one day per week (5) Those who have had abnormalities in clinical laboratory values or cardiopulmonary function, and are judged to have a problem participating in the study (6) Those who may develop allergies in relation to the study, those who are at risk of developing seasonal allergies such as hay fever during the research period (7) Those who have a disease that requires constant medication, those who have a disease under treatment, who have symptoms of memory impairment such as dementia or sleep disorders, or who are undergoing treatment those who have a history of serious disease that required medication (8) Those whose physical measurements, physical examination values, and clinical examination values before the start of intake were significantly out of the reference range (9) Those who work in shifts, work late at night, and have an irregular daily rhythm (10) Those who are participating in the other study within one month prior to the start of this study (11) Those who plan to become pregnant or breastfeed during the study period (12) Those who have a smoking habit (13) Those who are not good at blood sampling tests or those who have difficulty collecting blood (14) Those who are judged to be unsuitable as subjects based on the answers to the background survey (15) Those who are judged as unsuitable for the study by the investigator for other reason

Design outcomes

Primary

MeasureTime frame
cognitive function tests (Cognitrax long)

Countries

Japan

Contacts

Public ContactRio Fujiwara

EP Mediate Co., Ltd. Development Department Trial Planning Section

fujiwara.rio605@eps.co.jp070-7079-8488

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026